Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT

Z. DeFilipp; R. F. Duarte; J. A. Snowden; N. S. Majhail; D. M. Greenfield; J. L. Miranda; M. Arat; K. S. Baker; L. J. Burns; C. N. Duncan; M. Gilleece; G. A. Hale; M. Hamadani; B. K. Hamilton; W. J. Hogan; J. W. Hsu; Y. Inamoto; R. T. Kamble; M. T. Lupo-Stanghellini; A. K. Malone; P. McCarthy; M. Mohty; M. Norkin; P. Paplham; M. Ramanathan; J. M. Richart; N. Salooja; H. C. Schouten; H. Schoemans; A. Seber; A. Steinberg; B. M. Wirk; W. A. Wood; M. Battiwalla; M. E. D. Flowers; B. N. Savani; B. E. Shaw; CIBMTR Late Effects Quality Life; EBMT Complications Quality Life

doi:10.1038/bmt.2016.203

Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT

Z. DeFilipp, R. F. Duarte, J. A. Snowden, N. S. Majhail, D. M. Greenfield, J. L. Miranda, M. Arat, K. S. Baker, L. J. Burns, C. N. Duncan, M. Gilleece, G. A. Hale, M. Hamadani, B. K. Hamilton, W. J. Hogan, J. W. Hsu, Y. Inamoto, R. T. Kamble, M. T. Lupo-Stanghellini, A. K. MaloneP. McCarthy, M. Mohty, M. Norkin, P. Paplham, M. Ramanathan, J. M. Richart, N. Salooja, H. C. Schouten, H. Schoemans, A. Seber, A. Steinberg, B. M. Wirk, W. A. Wood, M. Battiwalla, M. E. D. Flowers, B. N. Savani, B. E. Shaw^*, CIBMTR Late Effects Quality Life, EBMT Complications Quality Life

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

31 Citations (Web of Science)

Abstract

Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with the estimated prevalence of MetS being 31-49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal of reviewing literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.

Original language	English
Pages (from-to)	173-182
Number of pages	10
Journal	Bone Marrow Transplantation
Volume	52
Issue number	2
DOIs	https://doi.org/10.1038/bmt.2016.203
Publication status	Published - Feb 2017

Keywords

LONG-TERM SURVIVORS
BONE-MARROW-TRANSPLANTATION
BODY-COMPOSITION ABNORMALITIES
ACUTE LYMPHOBLASTIC-LEUKEMIA
IMPAIRED GLUCOSE-TOLERANCE
RISK-FACTORS
DIABETES-MELLITUS
SCIENTIFIC STATEMENT
GLOBAL BURDEN
HEMATOLOGIC MALIGNANCIES

Access to Document

10.1038/bmt.2016.203

Cite this

DeFilipp, Z., Duarte, R. F., Snowden, J. A., Majhail, N. S., Greenfield, D. M., Miranda, J. L., Arat, M., Baker, K. S., Burns, L. J., Duncan, C. N., Gilleece, M., Hale, G. A., Hamadani, M., Hamilton, B. K., Hogan, W. J., Hsu, J. W., Inamoto, Y., Kamble, R. T., Lupo-Stanghellini, M. T., ... EBMT Complications Quality Life (2017). Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. Bone Marrow Transplantation, 52(2), 173-182. https://doi.org/10.1038/bmt.2016.203

@article{21ced3fb46c843349e31c11391921de3,

title = "Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT",

abstract = "Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with the estimated prevalence of MetS being 31-49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal of reviewing literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.",

keywords = "LONG-TERM SURVIVORS, BONE-MARROW-TRANSPLANTATION, BODY-COMPOSITION ABNORMALITIES, ACUTE LYMPHOBLASTIC-LEUKEMIA, IMPAIRED GLUCOSE-TOLERANCE, RISK-FACTORS, DIABETES-MELLITUS, SCIENTIFIC STATEMENT, GLOBAL BURDEN, HEMATOLOGIC MALIGNANCIES",

author = "Z. DeFilipp and Duarte, {R. F.} and Snowden, {J. A.} and Majhail, {N. S.} and Greenfield, {D. M.} and Miranda, {J. L.} and M. Arat and Baker, {K. S.} and Burns, {L. J.} and Duncan, {C. N.} and M. Gilleece and Hale, {G. A.} and M. Hamadani and Hamilton, {B. K.} and Hogan, {W. J.} and Hsu, {J. W.} and Y. Inamoto and Kamble, {R. T.} and Lupo-Stanghellini, {M. T.} and Malone, {A. K.} and P. McCarthy and M. Mohty and M. Norkin and P. Paplham and M. Ramanathan and Richart, {J. M.} and N. Salooja and Schouten, {H. C.} and H. Schoemans and A. Seber and A. Steinberg and Wirk, {B. M.} and Wood, {W. A.} and M. Battiwalla and Flowers, {M. E. D.} and Savani, {B. N.} and Shaw, {B. E.} and {CIBMTR Late Effects Quality Life} and {EBMT Complications Quality Life}",

year = "2017",

month = feb,

doi = "10.1038/bmt.2016.203",

language = "English",

volume = "52",

pages = "173--182",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "2",

}

DeFilipp, Z, Duarte, RF, Snowden, JA, Majhail, NS, Greenfield, DM, Miranda, JL, Arat, M, Baker, KS, Burns, LJ, Duncan, CN, Gilleece, M, Hale, GA, Hamadani, M, Hamilton, BK, Hogan, WJ, Hsu, JW, Inamoto, Y, Kamble, RT, Lupo-Stanghellini, MT, Malone, AK, McCarthy, P, Mohty, M, Norkin, M, Paplham, P, Ramanathan, M, Richart, JM, Salooja, N, Schouten, HC, Schoemans, H, Seber, A, Steinberg, A, Wirk, BM, Wood, WA, Battiwalla, M, Flowers, MED, Savani, BN, Shaw, BE, CIBMTR Late Effects Quality Life & EBMT Complications Quality Life 2017, 'Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT', Bone Marrow Transplantation, vol. 52, no. 2, pp. 173-182. https://doi.org/10.1038/bmt.2016.203

Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation : screening and preventive practice recommendations from CIBMTR and EBMT. / DeFilipp, Z.; Duarte, R. F.; Snowden, J. A. et al.

In: Bone Marrow Transplantation, Vol. 52, No. 2, 02.2017, p. 173-182.

Research output: Contribution to journal › (Systematic) Review article › peer-review

TY - JOUR

T1 - Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation

T2 - screening and preventive practice recommendations from CIBMTR and EBMT

AU - DeFilipp, Z.

AU - Duarte, R. F.

AU - Snowden, J. A.

AU - Majhail, N. S.

AU - Greenfield, D. M.

AU - Miranda, J. L.

AU - Arat, M.

AU - Baker, K. S.

AU - Burns, L. J.

AU - Duncan, C. N.

AU - Gilleece, M.

AU - Hale, G. A.

AU - Hamadani, M.

AU - Hamilton, B. K.

AU - Hogan, W. J.

AU - Hsu, J. W.

AU - Inamoto, Y.

AU - Kamble, R. T.

AU - Lupo-Stanghellini, M. T.

AU - Malone, A. K.

AU - McCarthy, P.

AU - Mohty, M.

AU - Norkin, M.

AU - Paplham, P.

AU - Ramanathan, M.

AU - Richart, J. M.

AU - Salooja, N.

AU - Schouten, H. C.

AU - Schoemans, H.

AU - Seber, A.

AU - Steinberg, A.

AU - Wirk, B. M.

AU - Wood, W. A.

AU - Battiwalla, M.

AU - Flowers, M. E. D.

AU - Savani, B. N.

AU - Shaw, B. E.

AU - CIBMTR Late Effects Quality Life

AU - EBMT Complications Quality Life

PY - 2017/2

Y1 - 2017/2

N2 - Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with the estimated prevalence of MetS being 31-49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal of reviewing literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.

AB - Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with the estimated prevalence of MetS being 31-49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal of reviewing literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.

KW - LONG-TERM SURVIVORS

KW - BONE-MARROW-TRANSPLANTATION

KW - BODY-COMPOSITION ABNORMALITIES

KW - ACUTE LYMPHOBLASTIC-LEUKEMIA

KW - IMPAIRED GLUCOSE-TOLERANCE

KW - RISK-FACTORS

KW - DIABETES-MELLITUS

KW - SCIENTIFIC STATEMENT

KW - GLOBAL BURDEN

KW - HEMATOLOGIC MALIGNANCIES

U2 - 10.1038/bmt.2016.203

DO - 10.1038/bmt.2016.203

M3 - (Systematic) Review article

C2 - 27548466

VL - 52

SP - 173

EP - 182

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -